Cansino Biologics Stock Fundamentals
| CJH Stock | EUR 3.66 0.02 0.54% |
CanSino Biologics fundamentals help investors to digest information that contributes to CanSino Biologics' financial success or failures. It also enables traders to predict the movement of CanSino Stock. The fundamental analysis module provides a way to measure CanSino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CanSino Biologics stock.
CanSino |
CanSino Biologics Company Shares Outstanding Analysis
CanSino Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current CanSino Biologics Shares Outstanding | 114.78 M |
Most of CanSino Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, CanSino Biologics has 114.78 M of shares currently outstending. This is 36.42% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all Germany stocks is 79.93% higher than that of the company.
CanSino Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CanSino Biologics's current stock value. Our valuation model uses many indicators to compare CanSino Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CanSino Biologics competition to find correlations between indicators driving CanSino Biologics's intrinsic value. More Info.CanSino Biologics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CanSino Biologics' earnings, one of the primary drivers of an investment's value.CanSino Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is rated below average in shares outstanding category among its peers.
CanSino Fundamentals
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Current Valuation | 3.4 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.77 % | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 2.21 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 1.03 B | |||
| EBITDA | 2.05 B | |||
| Net Income | 1.91 B | |||
| Cash And Equivalents | 6.71 B | |||
| Cash Per Share | 27.12 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 2.92 X | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.55 X | |||
| Number Of Employees | 1.95 K | |||
| Beta | 0.61 | |||
| Market Capitalization | 3.15 B | |||
| Total Asset | 11.87 B | |||
| Z Score | 46.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 11.87 B |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people.
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Stock
CanSino Biologics financial ratios help investors to determine whether CanSino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.